CANCERS TREATED WITH
ONCOLYTIC VIRUS THERAPY
One FDA approval in melanoma. Eight active indications at different evidence stages. Disease-specific evidence, platform, and trial accessibility differ substantially by cancer type.
analyticsAt a Glance
- check_circleMelanoma, head and neck cancers, glioblastoma, and bladder cancer are leading indications
- check_circleT-VEC (talimogene laherparepvec) is FDA-approved for injectable melanoma lesions
- check_circleH101 (Oncorine) has been approved in China for head and neck cancer since 2005
- check_circleClinical trials are exploring oncolytic viruses combined with checkpoint inhibitors
Disease-Specific Evidence Levels
Which cancers have the most compelling case reflects how immunologically cold the tumour is and how physically accessible it is for viral delivery.
| Cancer Type | Platform(s) | Key Data | Evidence Level |
|---|---|---|---|
| Melanoma | T-VEC (HSV-1) | 16.3% DRR; 10+ yr CRs; combo with pembrolizumab 62% ORR | FDA Approved |
| Glioblastoma | PVSRIPO, DNX-2401 | 21% OS at 36 mo (PVSRIPO); OS plateau in responders | Phase III ongoing |
| HCC | Vaccinia (Pexa-Vec), VG161 | Phase II activity; PHOCUS stopped (patient selection issue) | Phase I/II (redesigned) |
| HNSCC | T-VEC, CAVATAK | Intralesional T-VEC; CAVATAK ICAM-1 targeting | Phase II |
| Bladder (NMIBC) | CG0070 (adenovirus) | Intravesical for BCG-unresponsive; existing delivery route | Phase II/III |
| TNBC | Pelareorep + paclitaxel + atezo | Triple combination in active development | Phase II |
| Pancreatic | Pelareorep + gem/nab-pac | KRAS prevalence >90%; no Phase III OS benefit yet | Phase II |
Frequently Asked Questions
Disease Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Interested in Cancers Treated with Oncolytic Virus Therapy?
Upload your medical reports for a free evaluation. Our team will identify the most relevant oncolytic virus programmes and clinical trials for your specific diagnosis.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.